Bactiguard launches line extension to BIP CVC
Bactiguard is launching a line extension to its BIP CVC with the popular Raulerson syringe for easier handling and insertion. BIP CVC is shown to reduce the risk of costly blood stream infections, which are common following the use of central venous catheters.
"The demand for our BIP CVC is steadily increasing, and we are happy that we can now also offer a kit with the popular Raulerson syringe. It supports an insertion method used in many countries, where young doctors are trained using this procedure and it makes us even more competitive" , says Nina Nilsson, SVP Sales and Marketing at Bactiguard.
Catheter-related bloodstream infections are one of the most frequent, lethal, and costly complications of central venous catheterization and the most common cause of nosocomial bacteremia1. According to the World Health Organization, one case of CRBSI can cost up to USD 56 000 to treat. The US Center for Disease Control estimates that between 12% to 25% of patients who acquire CRBSI die2.
Bactiguard coated CVCs have been shown to reduce catheter-related infections in high-risk patients by up to 52%.3 Use of BIP CVC has also indicated improved blood compatibility properties in terms of lower risk of thrombosis compared to standard CVCs. In the same ex vivo study, BIP CVC was also shown to be non-hemolytic compared to other coated CVCs.4
The BIP CVC with Raulerson syringe is a line extension to the original product launched in 2013.
- Gahlot et al. International Journal of Critical Illness and Injury Science. 2014 Apr-Jun; 4(2): 162-167.
- WHO http://www.who.int/patientsafety/implementation /bsi/en/
- Goldschmidt H.et al., Zbl. Bakt.1995; 233: 215-223
- Vafa Homann et al. 2015, J. Biomed. Mater. Res. Part B Appl. Biomaterials
For further information, please contact:
Nina Nilsson, SVP Sales and Marketing, Mobile: +46 70 214 87 49
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com